摘要
目的 :探讨原癌基因 C- erb B- 2 ,癌基因 p5 3和增殖细胞核抗原 PCNA在乳腺癌中的表达和预后的关系以及在临床中的运用。方法 :80例乳腺癌石蜡切片标本免疫组化染色。结果 :C-erb B- 2 ,p5 3和 PCNA在乳腺癌中阳性率分别为 6 1.2 5 % ,5 0 % ,6 8.75 % ,其中 C- erb B- 2 ,PCNA与组织学分级 ,淋巴结有无转移成正相关 (P<0 .0 5 ) ,与雌激素受体水平呈负相关 (P<0 .0 1) ,而 p5 3与组织学分级 ,淋巴结转移情况及雌激素受体水平无相关性 (P>0 .0 5 )。结论 :C- erb B- 2 ,PCNA过表达者预后差 ,可以作为判断乳腺癌患者预后的有效指标 ,而 p5 3是乳腺癌发生的始动因素之一 ,可作为判断乳腺良、恶性病变的参考指标 。
Objective:To discuss the relationship between the expression of p53, C-erbB-2, PCNA and prognosis in breast carcinoma and their exertion in clinic.Methods:Eighty cases of paraffin-embedded specimens of breast carcinoma were studied by immunohistochemical study.Results:The positive rates of C-erbB-2, p53 and PCNA were 61.25 %,50 %,68.75 % respectively.The expression of C-erbB-2,PCNA were positively correlated with histological grading and lymph node metastases (P<0.05),and they were negatively correlated with the level of estrogen receptor. But there was no relationship between p53 and histological grading, lymph node metastases, or the level of estrogen receptor.Conclusion:The results suggested that the over-expression of C-erbB-2 and PCNA showed poor prognosis, and they can be effective markers for estimating the prognosis of breast cancer,while p53 is one of the initiative factors. It can be the referential marker in diagnosis of benign or malignant changes in breast, and it isn't the perfect prognostic marker.
出处
《肿瘤研究与临床》
CAS
2002年第5期330-331,共2页
Cancer Research and Clinic
